Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DDIT3
REST API REST API
Homo sapiens
DDIT3 is differentially expressed in 262 experiments: 92 organism parts: prostate, uterus, ... (90 more);, 116 disease states: normal, glioblastoma, ... (114 more);, 77 cell types 233 cell lines 32 compound treatments and 61 other conditions.
Synonyms CHOP10, GADD153, CHOP
Orthologs Ddit3 (Mus musculus)   DDIT3_BOVIN (Bos taurus)   Ddit3 (Rattus norvegicus)   ddit3 (Xenopus laevis)   DDIT3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to hydrogen peroxide, response to oxidative stress, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, cell redox homeostasis, transcription corepressor activity, cell cycle arrest, positive regulation of apoptosis, transcription factor binding, mRNA transcription from RNA polymerase II promoter, sequence-specific DNA binding, response to nutrient, cell cycle, protein dimerization activity, nucleus, aging, response to drug, response to DNA damage stimulus, endoplasmic reticulum unfolded protein response, endoplasmic reticulum membrane, response to endoplasmic reticulum stress, positive regulation of transcription, DNA-dependent, regulation of apoptosis, embryonic organ development, negative regulation of CREB transcription factor activity, ER overload response, response to amphetamine, negative regulation of canonical Wnt receptor signaling pathway, negative regulation of determination of dorsal identity, sequence-specific DNA binding transcription factor activity, regulation of DNA-dependent transcription in response to stress, negative regulation of sequence-specific DNA binding transcription factor activity
InterPro Term bZIP_2, TF_bZIP, DNA_damage_induc_transcript_3
UniProt Accession P35638, Q53YD1, F8VS99, F8W133
Gene-Disease Assocation MYXOID LIPOSARCOMA
Search EB-eye ENSG00000175197
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-GEOD-1577, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
PC3
2
E-MEXP-2034, E-GEOD-5258
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
K562
2
E-GEOD-24147, E-GEOD-96
COLO320DM
1
E-MTAB-37
LS1034
1
E-MTAB-37
227 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (42 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-360, E-MEXP-2019
naive B cell
1
E-TABM-702
CD16+ dendritic cell
1
E-TABM-34
monolayer recovery
1
E-GEOD-4219
leydig cell
1
E-MTAB-25
mesenchymal stem cell
1
E-GEOD-9894
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-GEOD-1577, ... (43 experiments)

Factor Value U/D Experiments
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
1
2
E-GEOD-4290, E-MTAB-37, E-MEXP-567
Anaplastic large cell lymphoma
1
E-MTAB-62
cancerous
1
E-TABM-15
110 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
glucose
1
E-MEXP-941
glutamine
1
E-MEXP-941
eicosapentaenoic acid
1
E-MEXP-1389
heregulin
1
E-GEOD-6462
mannitol
1
E-GEOD-6400
CNOT7+CNOT8
1
E-MEXP-2218
26 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-17385, E-GEOD-20847, E-GEOD-6431, E-MEXP-563

Genotype
studied in E-MEXP-1996, E-GEOD-1923, E-GEOD-21750, E-GEOD-22593, E-TABM-601, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (28 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-6802

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-147

Processing time: 0.391 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM